Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach

doi:10.5527/wjn.120295

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

(24)

(16)

(0)

(24)

(517)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Sep 25, 2026; 15(3): 120295
Published online Sep 25, 2026. doi: 10.5527/wjn.120295

Full Size Figure Download Figure

Figure 2 Mechanism of cardio-renal damage by mineralocorticoid receptor overactivation. DKD: Diabetic kidney disease; eNOS: Endothelial nitric oxide synthase; MRA: Mineralocorticoid receptor antagonist; NADPH: Nicotinamide adenine dinucleotide phosphate; NO: Nitric oxide; VSMC: Vascular smooth muscle cell; MR: Mineralocorticoid receptor.

Citation: Jose A, Kamrul-Hasan ABM, Fernandez CJ, Pappachan JM. Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach. World J Nephrol 2026; 15(3): 120295
URL: https://www.wjgnet.com/2220-6124/full/v15/i3/120295.htm
DOI: https://dx.doi.org/10.5527/wjn.120295

Jose A, Kamrul-Hasan ABM, Fernandez CJ, Pappachan JM. Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach. World J Nephrol 2026; 15(3): 120295 [PMID: 42626011 DOI: 10.5527/wjn.120295]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.